SG11202108857SA - Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells - Google Patents

Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells

Info

Publication number
SG11202108857SA
SG11202108857SA SG11202108857SA SG11202108857SA SG11202108857SA SG 11202108857S A SG11202108857S A SG 11202108857SA SG 11202108857S A SG11202108857S A SG 11202108857SA SG 11202108857S A SG11202108857S A SG 11202108857SA SG 11202108857S A SG11202108857S A SG 11202108857SA
Authority
SG
Singapore
Prior art keywords
lnterleukin
il2r
interleukin
variants
receptor
Prior art date
Application number
SG11202108857SA
Inventor
Ugur Sahin
Sina Fellermeier-Kopf
Alexander Muik
Matthias Birtel
Original Assignee
Biontech Cell & Gene Therapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Cell & Gene Therapies Gmbh filed Critical Biontech Cell & Gene Therapies Gmbh
Publication of SG11202108857SA publication Critical patent/SG11202108857SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202108857SA 2019-03-18 2020-03-16 Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells SG11202108857SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019056719 2019-03-18
PCT/EP2020/057140 WO2020187848A1 (en) 2019-03-18 2020-03-16 Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells

Publications (1)

Publication Number Publication Date
SG11202108857SA true SG11202108857SA (en) 2021-09-29

Family

ID=69780223

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108857SA SG11202108857SA (en) 2019-03-18 2020-03-16 Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells

Country Status (15)

Country Link
US (1) US20220177544A1 (en)
EP (1) EP3941935A1 (en)
JP (1) JP2022525921A (en)
KR (1) KR20210143759A (en)
CN (1) CN113874389A (en)
AU (1) AU2020242254A1 (en)
BR (1) BR112021016962A2 (en)
CA (1) CA3133414A1 (en)
CL (1) CL2021002407A1 (en)
CO (1) CO2021013687A2 (en)
CU (1) CU20210078A7 (en)
IL (1) IL285584A (en)
MX (1) MX2021011258A (en)
SG (1) SG11202108857SA (en)
WO (1) WO2020187848A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
DK2316852T3 (en) 2002-11-08 2014-06-16 Ablynx Nv Stabilized single-domain antibodies
PL1729795T3 (en) 2004-02-09 2016-08-31 Human Genome Sciences Inc Albumin fusion proteins
EP1723251A4 (en) * 2004-03-05 2008-04-23 Novartis Vaccines & Diagnostic In vitro test system for predicting patient tolerability of therapeutic agents
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
KR101193722B1 (en) 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 Exendin fusion proteins
CA2663042A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
CA2710835A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
AU2009242038B2 (en) 2008-05-02 2013-05-30 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
KR20130070576A (en) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 Albumin derivatives and variants
AR081454A1 (en) 2010-04-13 2012-09-05 Bristol Myers Squibb Co FIBRONECTINE-BASED ARMAZON DOMAIN PROTEINS THAT JOIN PCSK9 (KEXINA SUBTILISINE CONVERTASE CONVERTASE 9)
AU2012311451B2 (en) 2011-09-23 2017-08-10 Universitat Stuttgart Serum half-life extension using immunoglobulin binding domains
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
MA40721A (en) * 2014-08-06 2017-06-13 The Univ Of Miami INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 ALPHA RECEPTOR AND METHODS OF USE
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN112771072A (en) * 2018-07-24 2021-05-07 生物技术Rna制药有限公司 IL2 agonists

Also Published As

Publication number Publication date
CA3133414A1 (en) 2020-09-24
AU2020242254A9 (en) 2021-10-28
MX2021011258A (en) 2021-12-10
CL2021002407A1 (en) 2022-05-27
EP3941935A1 (en) 2022-01-26
AU2020242254A1 (en) 2020-09-24
CU20210078A7 (en) 2022-04-07
IL285584A (en) 2021-09-30
JP2022525921A (en) 2022-05-20
CO2021013687A2 (en) 2021-10-29
BR112021016962A2 (en) 2021-11-23
KR20210143759A (en) 2021-11-29
US20220177544A1 (en) 2022-06-09
CN113874389A (en) 2021-12-31
WO2020187848A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
IL284633A (en) Polypeptides comprising modified il-2 polypeptides and uses thereof
SG11202107354WA (en) Il-2 conjugates and methods of use thereof
SG11202011349PA (en) Activatable interleukin-2 polypeptides and methods of use thereof
IL289830A (en) Immune effector cell engineering and use thereof
EP3902837A4 (en) Monoclonal antibody against human interleukin-4 receptor alpha and use thereof
EP4081035A4 (en) Human ipsc-based derivation of nk and t-cells using early notch induction
EP3720470A4 (en) Il-2 muteins and uses thereof
IL290598A (en) Modified interleukin 2 (il-2) polypeptides, conjugates and uses thereof
EP3939609A4 (en) Liquid composition comprising antibody of human interleukin-4 receptor alpha
EP3904385A4 (en) Antibody against human il-4ra and use thereof
EP3978528A4 (en) Interleukin-4 receptor antibody and application thereof
EP3789486A4 (en) Immune effector cell and use thereof
EP3810656A4 (en) Human antibodies to human interleukin 18 receptor alpha and beta
SG11202108857SA (en) Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
EP3768281A4 (en) Compositions and methods for t-cell and cytokine activation
IL276599A (en) Mage-a1 specific t cell receptor and uses thereof
IL281339A (en) Antigen-specific t lymphocytes and methods of making and using the same
IL290433A (en) Interleukin-2 muteins for the expansion of t-regulatory cells
NZ749136A (en) Methods of immunotherapy
IL288536A (en) Il2 agonists
EP4036222A4 (en) Modified immune cell and use thereof
ZA202303645B (en) True human antibody specific for interleukin 1 alpha
PT3983387T (en) Sulfonylurea derivatives and uses thereof
IL286618A (en) Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers
EP3958851A4 (en) Allosteric activators of the alpha ia-adrenergic receptor